---
figid: PMC6827047__cancers-11-01618-g003
figtitle: Targeted components of the MAPK and AKT signaling cascades by small-molecule
  inhibitors in cancer
organisms:
- Mus musculus
- Rattus norvegicus
- Citrus trifoliata
- Aesculus hippocastanum
- Homo sapiens
- Canis lupus familiaris
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Canis lupus familiaris
- Drosophila melanogaster
pmcid: PMC6827047
filename: cancers-11-01618-g003.jpg
figlink: /pmc/articles/PMC6827047/figure/cancers-11-01618-f003/
number: F3
caption: 'Targeted components of the MAPK and AKT signaling cascades by small-molecule
  inhibitors in cancer. Effective targeting of the pathway intermediates is an efficient
  tactic in the case of constitutively activated signaling cascades, such as the MAPK
  pathway in cancer. Successful inhibition of a step in the cascade impairs the downstream
  progression of the pathway and its overall aberrant function. Combinations of inhibitors
  or multi-targeting molecules are being investigated, as they might provide more
  efficient manipulation of the entire signaling pathway. (MAPK: mitogen-activated
  protein kinase AKT: v-akt murine thymoma viral oncogene homolog 1).'
papertitle: 'A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer.'
reftext: Cornelia Braicu, et al. Cancers (Basel). 2019 Oct;11(10):1618.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8190593
figid_alias: PMC6827047__F3
figtype: Figure
redirect_from: /figures/PMC6827047__F3
ndex: 0056f981-df27-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6827047__cancers-11-01618-g003.html
  '@type': Dataset
  description: 'Targeted components of the MAPK and AKT signaling cascades by small-molecule
    inhibitors in cancer. Effective targeting of the pathway intermediates is an efficient
    tactic in the case of constitutively activated signaling cascades, such as the
    MAPK pathway in cancer. Successful inhibition of a step in the cascade impairs
    the downstream progression of the pathway and its overall aberrant function. Combinations
    of inhibitors or multi-targeting molecules are being investigated, as they might
    provide more efficient manipulation of the entire signaling pathway. (MAPK: mitogen-activated
    protein kinase AKT: v-akt murine thymoma viral oncogene homolog 1).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Akt1
  - Mtor
  - Apk
  - ras
  - Hras
  - Kras
  - Rem1
  - Pdk1
  - Pdpk1
  - Pten
  - Braf
  - Braf-rs1
  - Mapk3
  - Mapk1
  - Map2k1
  - Map2k2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - KRAS
  - HRAS
  - NRAS
  - PDK1
  - PDPK1
  - PTEN
  - BRAF
  - RPTOR
  - MAPK3
  - MAPK1
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - MAP2K1
  - MAP2K2
  - Akt
  - Tor
  - Nplp1
  - Ras64B
  - Ras85D
  - Crtc
  - rl
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Tie
  - InR
  - MKP-4
  - p38b
  - Dsor1
  - Sorafenib
  - Vemurafenib
  - Dabrafenib
  - Silimarin
  - rapamycin
  - Cancer
  - Lung cancer
---
